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Abstract 
Background: Hereditary non-polyposis colorectal cancer (HNPCC) is a 
common hereditary cancer predisposing syndrome has molecular and 
clinicopathological features still have remained ambiguous within Iranian 
populations. We discuss in this article some molecular and clinicopathological 
features of the condition. 
Methods: The study was a descriptive retrospective and designed on 1659 
colorectal cancer (CRC) patients were screened based on early-onset disease 
and Amsterdam II criteria during 14 years (2000-2013). 
Immunohistochemistry (IHC) staining was set up to detect expression of 
mismatch repair (MMR) genes on paraffin-embedded tissue sections of 31 
HNPCC-CRC tumors. SPSS 19 software was used to analyze the data. 
Results: IHC-MMR staining was absent in 7/31 individuals (22.6%) of which 
4 cases showed IHC-Absent (IHC-A) in both MSH2 and MSH6 (57.1%), in 2 
cases both MLH1 and PMS2 had negative staining (28.6%), and just in one 
case, MSH6 was defective (14.3%). The frequency of CRC among IHC-A and 
IHC-Present (IHC-P) families was 67.5% and 27.9%, respectively. Also the 
most frequent extracolonic cancers in IHC-A group were: stomach (10%), 
small bowel (5%), and prostate (5%); and in IHC-P group: stomach (18.4%), 
lung (10.9%), and breast (7.5%). Average age of IHC-A individuals at 
diagnosis was 38.0 versus 45.3 years in IHC-P individuals. Overall, 20.8% and 
57.1% of our index CRCs were localized proximal to the splenic flexure in 
IHC-P and IHC-A groups, respectively. 
Conclusion: Given the lack of enough information about molecular aspects of 
hereditary cancer syndromes like HNPCC in Iran, more evaluations are 
necessary on larger samples using complementary techniques such as MSI-
testing and mutation analyses. 
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Introduction 
Hereditary non-polyposis colorectal cancer 
(HNPCC) or Lynch syndrome (LS) is a chronic 
disease in which there is familial aggregation of 
colorectal cancer (CRC) and other associated tumors 
[1]. This disease now is described as a cancer 
susceptibility syndrome secondary to a germ-line 
mutation in at-least one of the DNA mismatch repair 
genes (MMRs) including MLH1, MSH2, MSH6, and 
PMS2 or some large deletion mutations in last exon 
of EPCAM, a gene located next to MSH2, or 
EPCAM-MSH2 locus [2, 3]. It leads to accumulate 
of mutations in other genes responsible to apoptosis 
and cell cycle control, accelerating an adenoma-to-
carcinoma transition event [3, 4]. Moreover, MLH1 
promoter hypermethylation, an epigenetic 
phenomenon, can inactivate the gene, mostly in 
sporadic CRCs [5, 6]. 
Screening for molecular detection is both time-
consuming and expensive due to the heterogeneity 
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of so variable mutations in MMRs [7]. Among two 
molecular screening tools which are being used 
commonly to detect LS, Microsatellite Instability 
(MSI) testing and immunohistochemical (IHC) 
staining of MMR proteins. MSI is sensitive but not 
specific for LS, as only 20–25% of all MSI-High 
(MSI-H) tumors are associated with germline 
mutations in a MMR gene. Although MSI has 
enough sensitivity to identify LS, it will not be 
detected in about 5% of all LS tumors [1]. 
MMR defects can be identified by IHC staining 
in tumor tissue sections in which expression of 
MMR genes is lost (IHC-Absent), while their 
expression in healthy adjacent tissue sections is 
intact (IHC-Present). IHC has about 77-100% 
sensitivity and 98-100% specificity to detect MMR 
defects compared to MSI-testing [4, 7-9]. 
Though, IHC has been reproduced as 
complement of MSI-testing in many studies [1, 10]. 
It has been suggested as the choice screening 
method prior to genetic testing by some authors 
[11]. They believe this technique has some 
advantages compared to MSI-testing and should be 
replaced as the first molecular screening tool [8]. 
IHC is more available than MSI as part of the 
routine service in the general pathology laboratories. 
In addition, IHC can be feasible at the time of 
colectomy efficiently [12]. Also, IHC is regarded 
more inexpensive than MSI, so earlier analysis 
indicated that IHC was about threefold less 
expensive than MSI-testing [13]. IHC, additionally, 
may consider as genetic testing because it can reveal 
which particular MMR gene may be defective, and 
as such it enables efficient mutation analysis on the 
target gene [8, 14]. Meanwhile, there are some 
limitations in IHC-MMRs such as uncertainty in 
interpretation due to variable tissue fixation and 
other technical issues which can result in weak or 
equivocal staining patterns [8]. It has also a low 
sensitivity to detect mutation of MLH1 with MLH1 
anti body alone, because it is possible that some 
missense mutations in this gene will not result in the 
absence of a detectable protein product [15]. 
Although the incidence of CRC has increased 
among Iranian population within 
recent decades [16, 17], it has not been yet 
established any systematic screening program to 
identify LS affected families among Iranian 
population. So, we designed a study to set up a 
molecular screening program in Central Iran for the 
first time. We discuss in this article the results of 
IHC-MMRs concluded from the study. 
Materials and Methods 
This study was a descriptive retrospective in 
order to screen CRC patients, in collaboration 
between two provinces: Isfahan and Charmahal va 
Bakhtiari, to identify HNPCC families. We screened 
1659 CRC patients registered in Poursina Hakim 
Research Center (PHRC), a famous referral 
gastroenterology clinic in Isfahan, center of Iran, 
during about 14 years from 2000 to the end of 2013. 
At first, we selected all patients with age of fifty 
years or less, as early-onset patients. Then using 
Amsterdam II criteria, at risk families for Lynch 
syndrome were included for next molecular 
analyses. These HNPCC families were called and 
invited for genetic counseling. Our study included 
all individuals participating in counseling sessions 
with history of bowel resection during the past 
decade whose paraffin-embedded blocks were 
available. During genetic counseling, the 
participants were interviewed about cancer related 
family history at-least up to three generations. The 
drawn pedigrees were reconfirmed by at-least two 
other members of every family. Moreover, the 
reported malignancies within families were possibly 
verified by searching for their medical documents, if 
available. Otherwise, we could trust them. Because 
according to strong familial relationship among 
Iranian people, they have usually awareness of 
serious diseases such as cancer in their relatives.  
Immunohistochemistry  
We tried to select one paraffin-embedded tissue 
block for each case from resected bowel specimen 
containing tumoral and preferably adjacent normal 
mucosa. About 1-2 µm. thick tissue sections were 
cut after that deparaffinized in xylene and rehydrated 
it through graded alcohols. 
Then slides were washed in running tap water, 
immersed in Tris-EDTA buffer at PH 9.0 in a 
pressure chamber at microwave for antigen retrieval 
for 20 minutes (5´ in high and 15´ in M-high 
degree). After washing the slides in deionized water, 
we used Peroxidase Block reagent to neutralize 
endogenous peroxidase for at-least 5 minutes. Then 
we washed the slides twice in TBS (Tris-buffered 
Saline), each time for 5 minutes. 
The slides were incubated with Protein Block 
reagent for 5 minutes and washed again in TBS 
twice as mentioned. The next step was incubation 
the slides overnight with optimally diluted mouse 
monoclonal primary antibodies as following: MSH2 
(Leica Biosystems: Novocastra, UK, Lyophilized, 
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Product Code (PC): NCL-MSH2) at 1/80 dilution, 
MLH1 (Leica Biosystems: Novocastra, UK, Liquid, 
PC: NCL-L-MLH1) at 1/100 dilution, MSH6 (Leica 
Biosystems: Novocastra, UK, Liquid, PC: NCL-L-
MSH6) at 1/100 dilution, and PMS2 (Leica 
Biosystems: Novocastra, UK, Liquid, PC: NCL-L-
PMS2) at 1/100 dilution. 
The next morning, after twice washing the 
slides in TBS, they were incubated with Post 
Primary Block reagent for 30 minutes. Washing 
again twice in TBS, we incubated the slides with 
Novolink Polymer for 30 minutes. Once again, twice 
washing in TBS with gentle rocking followed with 
developing peroxidase activity with DAB working 
solution for 5 minutes. Then we washed the slides in 
water and counterstained them with Hematoxylin. 
After rewashing the slides in water for 5 minutes, we 
finally dehydrated, cleared and mounted sections. 
Our slides were ready at the time for microscopic 
observation. 
Data Analysis 
We used SPSS 19 software package (SPSS Inc., 
Chicago, IL, USA) to analyze our data. 
 
Results 
Overall, of 1659 CRC patients registered in 
PHRC, 413 patients (24.9%) were ≤50 years at 
diagnosis. 219/413 successful calls, 45 HNPCC 
families were screened using Amsterdam II criteria 
of which 14 affected families were excluded from 
molecular testing stage. Of excluded families, 10 
individuals were omitted because of being 
unavailable their tumor tissues, and 4 others were 
excluded due to being unwilling for incorporation.  
IHC-MMR staining was absent in 7.31 of the 
individuals (22.6%) (IHC-A (Absent) versus IHC-P 
(present) families), of which 4 cases determined as 
IHC-A for both MSH2 and MSH6 antibodies 
Table 1. Frequency of cancer locations among Iranian HNPCC families in both IHC-A and IHC-P groups 
Cancer Locations 
IHC-P families IHC-A families 
frequency percent frequency percent 
colon / rectum 41 27.9 27 67.5 
Lung 16 10.9 1 2.5 
Stomach 27 18.4 4 10.0 
small bowel 7 4.8 2 5.0 
prostate 4 2.7 2 5.0 
brain 11 7.5 0 0.0 
haematopoietic system 6 4.1 2 5.0 
hepatobiliary system 5 3.4 1 2.5 
bladder 3 2.0 0 0.0 
testis  2 1.4 0 0.0 
thyroid  2 1.4 0 0.0 
kidney 1 0.7 0 0.0 
skin  2 1.4 0 0.0 
bone 2 1.4 0 0.0 
pancreas  1 0.7 0 0.0 
breast  11 7.5 1 2.5 
uterus  5 3.4 0 0.0 
nasopharynx 1 0.7 0 0.0 
Total 147 100.0 40 100.0 
HNPCC: Hereditary Non-polyposis Colorectal Cancer; IHC-A: Immunohistochemial Absent; IHC-P: 
Immunohistochemical Present 
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(57.1%), in 2 cases both MLH1 and PMS2 
antibodies showed IHC-A (28.6%), and just in one 
case MSH6 was defective (14.3%). PMS2 had no 
deficiency in all studied individuals.  
There were 187 cancer patients in all 31 
HNPCC families of which 40 affected members 
(~21%) were related to 7 IHC-A families. The mean 
of affected members in IHC-A families was 5.7 
while it was 6.1 in IHC-P families (p value=0.513).  
The most frequent cancers among IHC-A 
families were: CRC (67.5%), stomach (10%), small 
bowel (5%), and prostate (5%); while in IHC-P 
families: CRC (27.9%), stomach (18.4%), lung 
(10.9%), and breast (7.5%) were the most common 
cancers (Table 1).             
Mean age of IHC-A individuals at diagnosis 
was 38.0 years (range 31-50), while IHC-P 
individuals had averagely 45.3 years at diagnosis 
(range 24-69) (p value=0.146). On the other hand, 
the mean age of tumor diagnosis in 147 affected 
members within 24 IHC-P families was nearly the 
same as 40 cancer patients within 7 IHC-A families 
(~51 years: range 2-82 years). 
The most frequent colorectal cancer tumor sites 
among IHC-P individuals were: Rectum (41.7%), 
sigmoid colon (33.3%), cecum (12.5%), and 
ascending colon (8.3%); while in IHC-A 
individuals: ascending colon and descending colon 
(28.6%), and transverse colon, sigmoid colon and 
cecum (each one 14.3%) were the most common 
involved sites. Meanwhile, there was no case with 
rectum involvement among IHC-A individuals 
(Table 2).              
Just 1 of 7 IHC-A individuals (~14%) was 
diagnosed at I or II colorectal cancer TNM stage, 
while 8 of 24 IHC-P individuals (~33%) were found 
at these early stages (p value=0.345) (Table 3). 
Although 11/24 of IHC-P individuals (~46%) 
had been deceased at the screening time, 6.7 of IHC-
A individuals (~86%) were alive at this time 
(p=0.382). 
 
Discussion 
In this study we evaluated expression of MMR 
genes containing MLH1, MSH2, PMS2, and MSH6 
using IHC staining in 31 index early-onset CRC 
patients among identified HNPCC families within 
Isfahan, Iran for the first time.  
The gene expression is normal if nuclear 
staining in CRC cells would be observed intact as in 
normal adjacent epithelial cells. If nuclear staining is 
absent in cancer cells versus positive staining in 
nuclei of normal colon epithelial cells, it would be 
indicated defective expression of a gene [18].  
Prevalence of MMR deficiencies 
We found absent IHC-MMR staining in 22.6% 
of the early-onset HNPCC individuals (IHC-A) who 
had met Amsterdam II criteria. Given high 
sensitivity of four-antibody IHC-MMR to identify 
MSI-CRCs more than 92% [19], it seems a 
significant portion of Amsterdam positive families 
in our population has no MMR mutations. It suggests 
Table 2. Frequency of colorectal cancer tumor sites 
in Iranian HNPCC individuals in both IHC-A and 
IHC-P patients 
Tumor 
site 
IHC-P tumors IHC-A tumors 
Frequency Percent Frequency Percent 
cecum 3 12.5 1 14.3 
ascending 
colon 
2 8.3 2 28.6 
transverse 
colon 
0 .0 1 14.3 
descending 
colon 
0 .0 2 28.6 
sigmoid 
colon 
8 33.3 1 14.3 
rectum 10 41.7 0 .0 
unknown 1 4.2 0 .0 
Total 24 100.0 7 100.0 
 
Table 3. Frequency of colorectal cancer TNM stage at diagnosis time among Iranian HNPCC individuals in 
both IHC-A and IHC-P patients 
IHC-
MMR 
State 
Stage I Stage II Stage III Stage IV Total 
frequency percent frequency percent frequency percent frequency percent frequency percent 
Present 7 29.2 1 4.2 11 45.8 5 20.8 24 100 
Absent 0 0.0 0 14.3 0 71.4 1 14.3 7 100 
Total 7 22.6 2 6.5 16 51.6 6 19.4 31 100 
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the role of other genes in etiology of the most our 
samples. Although we cannot find definite data in 
Iranian population according to other studies, about 
35-70% of HNPCC families meeting Amsterdam 
criteria do not have MMR deficiency and are 
considered “Familial Colorectal Cancer Type X” 
(FCC-X) or “non-syndromic familial colorectal 
cancer” [20, 21]. It seems more evaluations on larger 
samples using complementary techniques such as 
MSI-testing and mutation analyses are necessary to 
estimate a more accurate frequency of X syndrome 
among Iranian population. 
The most frequent (~57%) deficiency of gene 
expression was related to both MSH2 and MSH6 
genes. MSH6 and PMS2 proteins are accessory to 
major MMR proteins: MSH2 and MLH1, 
respectively. So the loss of MSH2 expression in a 
tumor tissue leads to loss of MSH6 expression in 
that tissue. Germline mutations, however, in MSH6 
or PMS2, as minor MMR genes, lead to single loss 
of expression of their associated proteins [3]. 
Therefore, in 57% of our IHC-A individuals MSH2 
was responsible gene. The prevalence of MSH2 
defect in our study was near to some large early 
studies [22]. About 29% of the IHC-A tumors didn’t 
show any nuclear IHC-staining for both MLH1 and 
PMS2 proteins. It predicts existence of germline 
mutation in MLH1 of near to 30% of the IHC-A 
individuals. Although it is similar to some early 
valid studies [23], developing the IHC results by 
MSI-testing and mutation analyses, preferably on a 
larger sample, will be more informative.   
We found just one individual with absent IHC-
staining in MSH6 protein (14.3%). Interestingly, the 
genetic pedigree shows the number of affected 
relatives is fewer on average than MSH2 or MLH1 
families. So, there are only two cancer patients 
among second degree relatives of the individual with 
more than 65 years old. According to some studies, 
we expect the patients with MSH6 mutations would 
be more likely Amsterdam negative [24], so the 
Bethesda guidelines are more sensitive than the 
Amsterdam Criteria to identify it [25].  
Consequently, we may identify more patients with 
MSH6 defect among all our CRC patients using 
Bethesda guidelines. As some studies have 
presented, PMS2 loss in IHC-staining is the rarest 
event [26]. We found also no individual with absent 
IHC-staining singularly for PMS2. 
 
 
Clinicopathological features 
Although there was no significant difference 
between average count of cancer patients among the 
IHC-A and IHC-P HNPCC families, the frequency 
of CRC among IHC-A families was predominantly 
more than IHC-P families, nearly 2.5 fold (67.5% 
versus 27.9%), while we had asked cancer-related 
family history up to three generations in both 
groups.  
Moreover, the mean age at diagnosis in IHC-A 
individuals was more than 7 years earlier than IHC-
P individuals (38 versus 45.3 years), whereas there 
was no significant difference between other cancer 
patients in both groups of families (about 51 years). 
Studies on FCC-X families have shown that 
CRC risk among their kindred’s is lower than 
HNPCC families. Also, CRC diagnosis has occurred 
averagely 10-15 years later in FCC-X families [20, 
27]. Of our index CRCs, 20.8% and 57.1% were 
localized proximal to the splenic flexure in IHC-P 
and IHC-A groups, respectively (p<0.001).  
More studies on families with Amsterdam 
criteria, with and without MMR deficiency, have 
shown a higher proportion of CRCs are located 
proximally of the splenic flexure in patients with 
MMR deficiency than those with intact MMRs. For 
example, Mueller-Koch and his coworkers found 
68% of CRCs proximal to the splenic flexure in 
Amsterdam positive families with MMR mutations 
versus 14% in families without MMR mutations 
[27]. Some other authors have found similar results 
too [3, 28]. 
Although the proportion of our alive IHC-A 
individuals at screening to the alive IHC-P 
individuals was about 2 fold, the early-stage 
diagnosis among IHC-P individuals was more than 2 
fold of IHC-A individuals, according to their 
pathologic documents. It may refer to the better 
survival of MSI-CRCs compared to MSS 
(microsatellite stable) CRCs, a fact that has been 
considered in some studies. For example, in one 
study Malesci and his coworkers showed that MSI 
was significantly related to a reduced chance of 
lymph node and distant organ metastases at 
diagnosis [29]. 
Some authors have reported a genotype–
phenotype correlation in MMR mutation carriers. For 
example, MLH1 mutations are related to higher risk 
of early onset CRC cancer and more prevalent CRC 
cancer than extracolonic cancers, while in MSH2 
mutation carriers there was a higher risk of multiple 
Zeinalian et al. 
Iranian Journal of Cancer Prevention 
16 
extracolonic cancers, and the mean age of diagnosis 
is more than MLH1 mutation carriers [30, 31]. 
In our study, the patients with MLH1 defect 
were identified averagely 8 years earlier than the 
patients with MSH2 defect (~42 versus ~50 years 
old). In addition, there were more extracolonic 
cancer types among families with MSH2 defect in 
comparison to the families with MLH1 or MSH6 
defects (7 types versus 4 and 2 types, respectively). 
 The phenotype of MSH6 mutations is 
somewhat different than MLH1 and MSH2 
mutations, and this condition has been described as 
"MSH6 syndrome" [24]. The mean age at cancer 
diagnosis in MSH6 mutation carriers is at least one 
decade more than MSH2 or MLH1 mutation carriers 
[30]. In addition, the risk of CRC affection in 
families with MSH6 defect is more likely less than 
HNPCC families with MSH2 or MLH1 defects [32]. 
In our single family with MSH6 defect, the mean 
age of three cancer affected members at diagnosis 
was about 67 years, averagely two decades more 
than age of the patients in families with MLH1 or 
MSH2 defects. Moreover, the proportion of CRC 
patients was significantly lower than HNPCC 
families with MSH2 or MLH1 defects (33% versus 
72 and 66 percent respectively). 
 
Conclusion 
Since there is no enough information about 
molecular aspects of hereditary cancer syndromes 
like HNPCC in Iran, we have not still a definite 
known plan for molecular screening of the disease. 
Given the limitation of our study, we suggest more 
evaluations on larger samples by complementary 
techniques such as MSI-testing and mutation 
analyses to reach more trustworthy results. 
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